2 The technology
2.1 Edoxaban (Lixiana, Daiichi Sankyo) is an anticoagulant that directly inhibits factor X (factor Xa), which is a key component in the formation of blood clots. Edoxaban has a marketing authorisation for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. It is administered orally. The recommended dosage of edoxaban is 60 mg once daily, or 30 mg once daily in specific patient groups (people with renal impairment, low body weight [60 kg or less], or concomitant use of potent permeability glycoprotein [P‑glycoprotein] inhibitors), following treatment with a parenteral anticoagulant for at least 5 days.
2.2 The summary of product characteristics includes the following adverse reactions for edoxaban: bleeding, anaemia, nausea, rash, hepatobiliary disorders (increased blood bilirubin and gamma‑glutamyl transferase) and abnormal liver function test. For full details of adverse reactions and contraindications, see the summary of product characteristics.
2.3 Edoxaban costs £2.10 per 15‑mg, 30‑mg or 60‑mg tablet (excluding VAT) and the daily cost of treatment is £2.10. Costs may vary in different settings because of negotiated procurement discounts.